Two Sigma Investments LP Purchases Shares of 437,185 ASP Isotopes Inc. (NASDAQ:ASPI)

Two Sigma Investments LP acquired a new stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 437,185 shares of the company's stock, valued at approximately $1,980,000. Two Sigma Investments LP owned approximately 0.61% of ASP Isotopes as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ASPI. BNP Paribas Financial Markets acquired a new stake in ASP Isotopes during the fourth quarter valued at approximately $34,000. Avantax Advisory Services Inc. acquired a new stake in ASP Isotopes during the fourth quarter valued at approximately $45,000. Russell Investments Group Ltd. raised its position in shares of ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company's stock worth $46,000 after purchasing an additional 3,682 shares during the period. SVB Wealth LLC acquired a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $49,000. Finally, Boston Financial Mangement LLC acquired a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 16.80% of the company's stock.

ASP Isotopes Stock Performance

Shares of ASP Isotopes stock traded down $0.08 on Thursday, reaching $8.76. 4,161,473 shares of the company were exchanged, compared to its average volume of 2,667,826. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The company's 50-day moving average is $6.22 and its two-hundred day moving average is $5.48. The firm has a market cap of $657.54 million, a price-to-earnings ratio of -14.36 and a beta of 3.40. ASP Isotopes Inc. has a 1-year low of $1.86 and a 1-year high of $9.33.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group increased their price target on ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st.

Insider Buying and Selling

In related news, CEO Paul Elliot Mann sold 316,667 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total value of $1,820,835.25. Following the completion of the transaction, the chief executive officer now directly owns 7,948,787 shares of the company's stock, valued at $45,705,525.25. This represents a 3.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Robert Ainscow sold 66,668 shares of the stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $374,674.16. Following the completion of the transaction, the chief operating officer now directly owns 1,419,992 shares of the company's stock, valued at $7,980,355.04. This trade represents a 4.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 766,667 shares of company stock valued at $4,358,502 in the last three months. 21.40% of the stock is currently owned by corporate insiders.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.